<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125567</url>
  </required_header>
  <id_info>
    <org_study_id>2939111</org_study_id>
    <secondary_id>EudraCT number: 2004-005234-39</secondary_id>
    <nct_id>NCT00125567</nct_id>
  </id_info>
  <brief_title>Stalevo in Early Wearing-Off Patients</brief_title>
  <acronym>SEWOP</acronym>
  <official_title>Multicentre, Randomised, Double-Blind Study to Compare Stalevo to Levodopa/Carbidopa in Patients With Parkinson's Disease Experiencing Symptoms of Early Wearing-Off</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate in patients with Parkinson's disease that, when
      compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to
      the time an increase in antiparkinsonian medication is required due to inadequately
      controlled parkinsonian symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time until a patient requires changes in antiparkinsonian therapy due to inadequately controlled parkinsonian symptoms</measure>
    <time_frame>Up to 2 years of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale</measure>
    <time_frame>Up to 2 years of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (investigator)</measure>
    <time_frame>Up to 2 years of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Questionnaire (PDQ-39)</measure>
    <time_frame>Up to 2 years of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Impairment Questionnaire</measure>
    <time_frame>Up to 2 years of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">223</enrollment>
  <condition>Idiopathic Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stalevo (levodopa/carbidopa/entacapone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levodopa/carbidopa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stalevo (levodopa/carbidopa/entacapone)</intervention_name>
    <description>Oral, 50-150 mg levodopa four times daily, for up to 2 years</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa/carbidopa</intervention_name>
    <description>Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic Parkinson's disease

          -  Treatment with 3 equal daily doses of levodopa/carbidopa up to 450 mg/day

          -  Unchanged antiparkinsonian medication for 6 weeks prior to baseline

        Exclusion Criteria:

          -  Secondary or atypical parkinsonism

          -  Patients with daily unpredictable OFF periods or painful dyskinesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Wighton, BSc (Hons)</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bhadravati SD Sastry, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Wales and Rookwood Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9000 Aalborg</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Århus Kommunehospital</name>
      <address>
        <city>Nørrebrogade 44</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Karelia Central Hospital</name>
      <address>
        <city>Lappeenranta</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521 Tampere</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson Klinik Bad Nauheim</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231 Bad Nauheim</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik Bad Neustadt</name>
      <address>
        <city>Bad Neustadt</city>
        <zip>97616 Bad Neustadt</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik der Universitat Dusseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225 Duesseldorf</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21075 Hamburg</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Drs Lang, Krauss, Schreiber</name>
      <address>
        <city>Ulm</city>
        <zip>89073 Ulm</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset MAS</name>
      <address>
        <city>Malmö</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Läkarhuset Vällingby</name>
      <address>
        <city>Vällingby</city>
        <zip>SE-162 68</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Movement Disorder Services</name>
      <address>
        <city>Chertsey</city>
        <state>Surrey</state>
        <zip>KT16 0QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glan Clwyd Hospital</name>
      <address>
        <city>Rhyl</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frenchay Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS16 1LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leigh Infirmary</name>
      <address>
        <city>Leigh</city>
        <zip>WN7 1HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2005</study_first_submitted>
  <study_first_submitted_qc>July 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2005</study_first_posted>
  <last_update_submitted>June 19, 2009</last_update_submitted>
  <last_update_submitted_qc>June 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Andrew Wighton</name_title>
    <organization>Orion Pharma</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Entacapone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

